Biomarker-driven mechanisms and therapeutic targets for prostate diseases through mendelian randomization and molecular docking
Abstract
BACKGROUND: Prostate diseases, comprising prostatitis, benign prostatic hyperplasia (BPH), and prostate cancer (PCA), represent substantial public health burdens. This study aimed to clarify biomarker-disease relationships and identify potential therapeutic targets for prostate disorders using a Mendelian Randomization (MR) framework.
METHODS: We conducted two-sample MR analyses using genome-wide association data. Causal effects were estimated using complementary MR methods. To identify therapeutic targets, MR findings were integrated with DrugBank, protein-protein interaction networks, bulk RNA sequencing, and molecular docking.
RESULTS: Six biomarkers showed causal effects on prostate diseases: URK on prostatitis; GGT and TBIL on BPH; and UCR, PHOS, and BUN on PCA. Functional integration highlighted MPO and TUBB as drug targets for BPH, while docking implicated MET and ATP8B1 in BPH and GATA3 and ENPP3 in PCA. Drug repurposing suggested dexamethasone for BPH and colchicine and metformin for PCA.
CONCLUSION: This study provides genetic evidence linking biomarkers to prostate diseases and identifies novel druggable targets and repurposing opportunities, offering mechanistic insights and prospects for precision therapy.
This article applies two-sample Mendelian randomization to establish causal relationships between circulating biomarkers and prostate diseases.Identified six key biomarkers with significant causal effects on prostatitis, BPH, and prostate cancer.Integrated…
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.